The firm said it also plans to add 400 staff to the site at its current in production line or laboratory positions. The site currently employs more than 600 employees across manufacturing, R&D, and administration.
According to an Amneal spokesperson, the additional space at South Yaphank would house additional manufacturing and testing equipment, including quality control (QC) capabilities, to increase the production of generic medications made at the site. The generics manufacturer added the expansion would allow it to respond more quickly to demand for its products.
These include oral solids, softgels, high potency and oncological medicines, hormonal medicines, and controlled substances.
Cost, available land, and zoning – to determine whether planning permission for a given development would be granted – must be assessed before the firm expands the site, the spokesperson told us.
“Also, in anticipation of Amneal’s merger with Impax Laboratories closing this spring (subject to SEC [Securities and Exchange Commission] approval), Amneal expects to bring manufacture of some Impax drugs in-house, including at South Yaphank,” the spokesperson said.
In October last year, the firms announced the all-stock transaction, under which Amneal Holdings members would own approximately 75%, and Impax shareholders 25%. The firms are awaiting SEC clearance for the deal to go through.
“Impax now uses third parties to produce some of its product,” the spokesperson told us.
Amneal did not disclose which vendors would be fitting out the facility.
“Amneal will continue to work with local construction firms and other contractors on Long Island, but no specific information is available at this time,” we were told.
Neither the cost of the expansion, nor the completion date were disclosed.